Relapsed/Refractory Multiple Myeloma

$Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma$

Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma

Post author:Austin Newman
Post published:March 15, 2026
Post category:Multiple Myeloma

As reported on drugs.com, Bristol Myers Squibb (BMS) has announced encouraging interim results from the Phase 3 portion of the SUCCESSOR-2 clinical trial evaluating oral mezigdomide in patients with relapsed…

$Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma$

qimono / Pixabay

Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

Post author:Rose Duesterwald
Post published:January 7, 2021
Post category:Multiple Myeloma

According to a recent report in Cancer Network, the results from CARTITUDE-1 were well received. CARTITUDE-1 is a phase 1b/2 clinical trial of the CAR T-cell treatment, Cilta-Cel, for the…

Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma

Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

Let’s Work Together!

Keep Up to Date

Learn More